Twist Bioscience (NASDAQ:TWST) Insider Sells $19,732.75 in Stock

Key Points

• Dennis Cho, an insider at Twist Bioscience, sold 425 shares on March 6 at $46.43 for $19,732.75, reducing his stake to 138,257 shares; he has also executed larger sales in February and December.
• Twist reported Q results with EPS of ($0.50) that missed estimates while revenue of $103.7M beat expectations, though the company remains unprofitable with a negative net margin (~19.6%) and negative ROE.
• The stock trades in the mid-$40s (around $45.40) with a $2.78B market cap, a 50-day/200-day moving average of $43.92/$34.80, and a consensus analyst rating of Moderate Buy (consensus target ~$45.88) amid several recent price-target upgrades to ~$50–$52.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 425 shares of Twist Bioscience stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $46.43, for a total transaction of $19,732.75. Following the sale, the insider owned 138,257 shares of the company's stock, valued at approximately $6,419,272.51. The trade was a 0.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Dennis Cho also recently made the following trade(s):

• On Wednesday, February 11th, Dennis Cho sold 5,000 shares of Twist Bioscience stock. The stock was sold at an average price of $49.93, for a total transaction of $249,650.00.
• On Tuesday, February 3rd, Dennis Cho sold 1,099 shares of Twist Bioscience stock. The stock was sold at an average price of $46.58, for a total transaction of $51,191.42.
• On Monday, December 22nd, Dennis Cho sold 324 shares of Twist Bioscience stock. The shares were sold at an average price of $34.56, for a total transaction of $11,197.44.

Twist Bioscience Stock Performance

NASDAQ:TWST traded down $2.93 during mid-day trading on Tuesday, hitting $45.40. The company's stock had a trading volume of 851,196 shares, compared to its average volume of 1,381,620. The business's fifty day moving average is $43.92 and its two-hundred day moving average is $34.80. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of -35.47 and a beta of 2.23. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $57.88.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). The company had revenue of $103.70 million for the quarter, compared to analysts' expectations of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company's quarterly revenue was up 16.9% on a year-over-year basis. Analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Institutional Trading of Twist Bioscience

Several large investors have recently bought and sold shares of the business. Campbell & CO Investment Adviser LLC lifted its position in Twist Bioscience by 227.6% during the third quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company's stock worth $1,328,000 after buying an additional 32,792 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in Twist Bioscience by 14.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company's stock valued at $41,171,000 after buying an additional 184,726 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of Twist Bioscience by 62.8% in the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company's stock worth $35,533,000 after acquiring an additional 487,052 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of Twist Bioscience by 14.0% during the 3rd quarter. New York State Common Retirement Fund now owns 584,694 shares of the company's stock worth $16,453,000 after acquiring an additional 71,777 shares during the period. Finally, William Blair Investment Management LLC boosted its position in shares of Twist Bioscience by 6.0% during the 3rd quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company's stock valued at $116,564,000 after acquiring an additional 235,679 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have weighed in on TWST. Evercore upped their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research report on Monday, December 29th. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, February 3rd. TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Finally, Barclays lifted their price objective on Twist Bioscience from $39.00 to $50.00 and gave the stock an "overweight" rating in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $45.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.